COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies
- Creators
- Passamonti F.
- Romano A.
- Salvini M.
- Merli F.
- Porta M. G. D.
- Bruna R.
- Coviello E.
- Romano I.
- Cairoli R.
- Lemoli R.
- Farina F.
- Venditti A.
- Busca A.
- Ladetto M.
- Massaia M.
- Pinto A.
- Arcaini L.
- Tafuri A.
- Marchesi F.
- Fracchiolla N.
- Bocchia M.
- Armiento D.
- Candoni A.
- Krampera M.
- Luppi M.
- Cardinali V.
- Galimberti S.
- Cattaneo C.
- La Barbera E. O.
- Mina R.
- Lanza F.
- Visani G.
- Musto P.
- Petrucci L.
- Zaja F.
- Grossi P. A.
- Bertu L.
- Pagano L.
- Corradini P.
- Derenzini E.
- Marchetti M.
- Scattolin A. M.
- Corso A.
- Tosi P.
- Gherlinzoni F.
- Passerini C. G.
- Cavo M.
- Fava C.
- Turrini M.
- Visco C.
- Zappasodi P.
- Merli M.
- Mora B.
- Vannucchi A. M.
- Others:
- Passamonti, F.
- Romano, A.
- Salvini, M.
- Merli, F.
- Porta, M. G. D.
- Bruna, R.
- Coviello, E.
- Romano, I.
- Cairoli, R.
- Lemoli, R.
- Farina, F.
- Venditti, A.
- Busca, A.
- Ladetto, M.
- Massaia, M.
- Pinto, A.
- Arcaini, L.
- Tafuri, A.
- Marchesi, F.
- Fracchiolla, N.
- Bocchia, M.
- Armiento, D.
- Candoni, A.
- Krampera, M.
- Luppi, M.
- Cardinali, V.
- Galimberti, S.
- Cattaneo, C.
- La Barbera, E. O.
- Mina, R.
- Lanza, F.
- Visani, G.
- Musto, P.
- Petrucci, L.
- Zaja, F.
- Grossi, P. A.
- Bertu, L.
- Pagano, L.
- Corradini, P.
- Derenzini, E.
- Marchetti, M.
- Scattolin, A. M.
- Corso, A.
- Tosi, P.
- Gherlinzoni, F.
- Passerini, C. G.
- Cavo, M.
- Fava, C.
- Turrini, M.
- Visco, C.
- Zappasodi, P.
- Merli, M.
- Mora, B.
- Vannucchi, A. M.
Description
COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04–11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11–1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.
Additional details
- URL
- http://hdl.handle.net/11567/1078676
- URN
- urn:oai:iris.unige.it:11567/1078676
- Origin repository
- UNIGE